NEW LIMITATION CHANGE

TO
Approved for public release, distribution unlimited

FROM
Distribution authorized to U.S. Gov't. agencies and their contractors; Foreign Government Information; 09 MAR 1967. Other requests shall be referred to US Army Fort Detrick, Attn: Technical Release Branch [TID], Frederick, MD 21701.

AUTHORITY
SMUFD d/a ltr, 15 Feb 1972
DDC AVAILABILITY NOTICE

Reproduction of this publication in whole or in part is prohibited. However, DDC is authorized to reproduce the publication for United States Government purposes.

STATEMENT #2 UNCLASSIFIED

This document is subject to special export controls and each transmittal to foreign governments or foreign nationals may be made only with prior approval of Dept. of Army, Fort Detrick, ATTN: Technical Release Branch/ TID, Frederick, Maryland 21701

DEPARTMENT OF THE ARMY
Fort Detrick
Frederick, Maryland
CONSIDERATIONS ON THE USE OF CEPHAL RIDINE IN HUMAN PATHOLOGY

Minerva Medica
(Medical Minerva)
Vol. 57, No. 47, pages 2161-2175, 1966

It is the purpose of this report to present a mostly practical clinical contribution to the knowledge of the activity of a new antibiotic, a semi-synthetic derivative of cephalosporine C which is obtained through biosynthesis from microorganisms belonging to the genus Cephalosporium (11, 38, 39).

The production of substances endowed with an antibiotic activity by organisms of this kind was brought out for the first time in Sardinia by Giuseppe Brotsu (9, 10) in the course of research undertaken to identify new antibiotics of natural origin.

The study of metabolites with the antibiotic action of Cephalosporium was then continued in Great Britain and seven new substances with antibiotic action were isolated (10, 19, 21). The most active among them turned out to be Cephalosporium P, Cephalosporium W ("synnematin"), which acts primarily through gram-negative germs (8, 36), and Cephalosporium C (27). The central nucleus of the latter is 7-aminoccephalosporanic acid, similar to the nucleus of penicillin, that is 6-aminopenicillanic acid (2, 15, 28) (Figure 1).
Figure 1. 6-amino-penicillanic acid and 7-amino-cephalasporanic acid.

The nucleus of cephalosporine C can currently be synthesized (5, 37, 38, 39, 42) and, by means of a number of substitutions, either in position 7, or at the expense of the acetoxylic group in position 3, it was possible to obtain a very large number of compounds. Many of these compounds, which proved to be active in vitro, on the other hand turned out to have a rather modest activity in vivo, since they are easily hydrolyzable in position 3 by means of organic esterases (11, 18, 25, 33).

Substituting the acetoxylic group in position 3 with pyridine, the organic esterases cannot split the compound since there is no longer any esteratic bond.

Among the various components synthesized with this criterion in mind, the Research Division of Glaxo synthesized cephaloridine by introducing the 7-thymyl-acetic radical into position 7: This resulted in the internal salt of 7-(2-thymyl)-acetamido7-3-(1-pyridylmethyl)-3-cephem-4-carboxylic acid (7, 12) (Figure 2).

Figure 2. Cephaloridine = internal salt of 7-(2-thymyl)-acetamido7-3-(1-pyridylmethyl)-3-cephem-4-carboxylic acid.

Cephaloridine acts through a bactericidal effect (7, 32) upon gram-positive and gram-negative microorganisms, whereas it is inactive toward fungi, protozoa, helminths, as well as aerobacter aerogenes, pseudomonas pyocyanae; it is hardly active toward mycobacterium tuberculosis (32, 41).

It is an antibiotic which resists penicillinase and the bacterial resistance without manifestations of crossed resistance with penicillin (1, 3, 6, 7, 13, 30, 43).

On the basis of laboratory investigations and on the basis of the first clinical applications (28, 40), cephaloridine appears to be perfectly well tolerated and absolutely devoid of any toxic effects when administered in clinical doses.
The maximum concentration in the human blood, after intramuscular administration of a dose of 0.5 g is reached after the first hour (3-10 gamma/cc) and the average stay of this concentration in the blood may vary from 4-5 hours; however, during the 8th hour, we still find gamma 1-2/cc in a circle (32); cephaloridine is eliminated completely through the kidneys and the form of urinary elimination occurs without any modifications, since it has been demonstrated that it reveals a distinct stability with respect to intracellular transformations.

In the course of clinical use, it has proved to be very active in a number of different affections which sometimes resisted treatment with other antibiotics (17, 20, 22, 23, 40).

After this introduction we would like to present the practical results derived from this antibiotic in a rather varied group of case histories, such as we found it at the special medical pathology institute of the University of Cagliari.

Since it is known that antibiotics develop a toxic action on the level of numerous organs and apparatuses, including first of all the liver and the kidney, we also directed our attention to the possible influence of the antibiotic we are studying here upon the functional activities of the liver cell.

Case Histories

Our research involved 65 patients who revealed various affections which we can group as follows:

(1) Affections involving the kidneys and the urinary tracts, nine cases;
(2) Affections of the respiratory system: 32 cases;
(3) Septic affections of the liver and of the bile ducts: eight cases;
(4) Cardiac affections: four cases;
(5) Miscellaneous affections: 12 cases.

In tables 1, 2, 3, 4, and 5 we show the diagnoses for each group of affections in detail.

(1) Therapy plan. Cephaloridine was administered at the rate of 1-3 g per day as attack dose and this was reduced after a period of time varying from one case to the next, to the maintenance dose of 1 g per day.

Along with this antibiotic, as well as all of the other antibiotics considered in this study, we also administered abundant doses of vitamins of the B group.

(2) Research plan. In order to evaluate the therapeutic effect of the
administration of cephaloridine in all of the patients treated here, we took into consideration not only the fever curve, the blood pressure and the pulse, but also the speed of sedimentation, the number of leukocytes, the leucocytyric formula and the mucoproteins. In lung patients we dosed the quantity of the expectorate and we made numerous x-ray checks.

Accurate controls were performed on the urine in patients suffering from diseases of the urinary apparatus. In patients with diseases of the circulatory system we also examined the antistreptolysinic index. In patients with diseases of the bile ducts we attached particular importance to tests that would express the progress of the retentive state; we evaluated not only the behavior of bilirubinemia but also that of alkaline phosphatase, cholesterol, and the gamma and alpha2 globulins; the latter were studied by means of electrophoresis on acetylcellulose.

For the purpose of bringing out any possible negative effect of the antibiotic upon the liver cell, we also made a study of the synthetic activities of the liver in all of these patients who were treated with cephaloridine; here we used the following tests: serum albuminemia dosage by means of electrophoresis, dosage of the prothrombin activity (in icterus patients only after the addition of vitamin K), as well as dosage of the V factor, the VII factor, and cholinesterase.

As far as the evaluation of the liver's secretion capacity is concerned, we used the study of the elimination of amsulfoxalphtaleine, of Cardio-Green, and of bilirubin in all of its fractions.

The study of the behavior of glycosemia, anotemia, and cholesterolemia then completed our research.

Results

Afections of the urinary tracts. The response to the action of cephaloridine was truly one of the most effective and prompt (Table 1).
<table>
<thead>
<tr>
<th>(a)</th>
<th>(b)</th>
<th>(c)</th>
<th>(d)</th>
<th>(e)</th>
<th>(f)</th>
<th>(g)</th>
<th>(h)</th>
<th>(i)</th>
<th>(j)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>N.L.</td>
<td>Glenorulonephritis acuta</td>
<td>2</td>
<td>21</td>
<td>2</td>
<td>37.5</td>
<td>34</td>
<td>5.000</td>
<td>4.000</td>
</tr>
<tr>
<td>2</td>
<td>L.O.</td>
<td>Pyelonephritis acuta con infarto piograo suppurato</td>
<td>1</td>
<td>10</td>
<td>9</td>
<td>100</td>
<td>90</td>
<td>7.500</td>
<td>6.100</td>
</tr>
<tr>
<td>3</td>
<td>M.V.</td>
<td>Pyelonephritis acuta</td>
<td>1.5</td>
<td>9</td>
<td>2</td>
<td>49.5</td>
<td>18.5</td>
<td>9.000</td>
<td>8.000</td>
</tr>
<tr>
<td>4</td>
<td>M.E.</td>
<td>Nephrosis prostatic:</td>
<td>1</td>
<td>11</td>
<td>3</td>
<td>41.5</td>
<td>30</td>
<td>6.300</td>
<td>4.300</td>
</tr>
<tr>
<td>5</td>
<td>F.D.</td>
<td>Cistitis</td>
<td>2</td>
<td>10</td>
<td>3</td>
<td>37</td>
<td>28</td>
<td>11.300</td>
<td>9.200</td>
</tr>
<tr>
<td>6</td>
<td>C.A.</td>
<td>Nephrosis consequente al trauma orassico</td>
<td>1.5</td>
<td>8</td>
<td>2</td>
<td>42.5</td>
<td>28.5</td>
<td>12.500</td>
<td>10.200</td>
</tr>
<tr>
<td>7</td>
<td>A.L.</td>
<td>Glenorulonephritis acuta</td>
<td>1</td>
<td>11</td>
<td>3</td>
<td>35</td>
<td>27</td>
<td>18.000</td>
<td>14.200</td>
</tr>
<tr>
<td>8</td>
<td>R.L.</td>
<td>Glenorulonephritis acuta</td>
<td>1</td>
<td>10</td>
<td>6</td>
<td>45</td>
<td>22</td>
<td>12.000</td>
<td>7.000</td>
</tr>
<tr>
<td>9</td>
<td>M.L.</td>
<td>Cistitis acuta in soggetto aff. per papilla discal agit ilieti con disturbi dell'usura pro erina discal</td>
<td>1.5</td>
<td>10</td>
<td>2</td>
<td>90</td>
<td>60</td>
<td>9.200</td>
<td>6.500</td>
</tr>
</tbody>
</table>

Legend: a--number; b--patient's initials; c--form of disease; d--cephaloridine; e--VES/sedimentation rate (Kats index); f--leucocytes; g--duration of treatment (days); h--fever drop after number of days; i--before; j--after; k--result; l--excellent; m--excellent; n--good; 1--acute glomerulonephritis; 2--specific pyelonephritis with superposed infected pyogen; 3--acute pyelonephritis; 4--prostatic neoplastic; 5--cystitis; 6--hyperthermia following urological examination; 7--acute glomerulonephritis; 9--acute cystitis in subject suffering from flaccid paralysis of the lower limbs, with disorders in sphincters due to discal hernia.

The germs which were recognised most. frequently here as being responsible for the infection were: *Coli* and *enterococcus*.

Figure 3 describes the time of fever drop from the beginning of the therapy pursued in the nine cases considered here. From this we can deduce that the fever drop occurred during a period of time which can vary from a minimum of 2 to a maximum of 9 days.
Figure 3. Legend: 1--affections of the kidneys and urinary tract; 2--time of fever drop from beginning of treatment; 3--days; 4--patients' initials.

It might be worth while to point out here one case of renal tuberculosis with superposed infected pyogen, combined with a finding of Koch bacillus which was rather empyem positive in the urine; in this case the temperature was particularly resistant to the specific treatment because of a cystitis superposed by pyogens.

The use of cephaloridine brought the temperature down within 9 days; as the disease continued and for the period of time during which we were possible to observe the patient directly, the temperature turned out to be rather modest although it was a little more than 37.3-37.5°C; this was accompanied by a completely negative urine report in the sense of the pyogenic process (figure 4).

Figure 4. 2.0.: renal tuberculosis with superposed infected pyogen. Legend: a--streptomycin 1 g/day; b--cephaloridine, 1 g/day; c--days.
The antibiotic dose used in these disease forms was about 2 g during the attack phase and 1 g during the maintenance phase.

Affections of the Respiratory System. The affections of the respiratory system are represented above all by patients suffering from bronchial pneumonia and bronchitis, often complicated by an astmatic ailment. Here our case histories were relatively more numerous and this gave us a better chance to use our antibiotic (Table 2).
TABLE 2
SUMMARY TABLE OF CASE HISTORIES
OF THE RESPIRATORY SYSTEM, TREATED WITH CEPHALORIDINE

<table>
<thead>
<tr>
<th>Case</th>
<th>Initial Diagnosis</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>2</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>3</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>4</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>5</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>6</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>7</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>8</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>9</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
<tr>
<td>10</td>
<td>Bronchial asthma</td>
<td>Cephaloridine</td>
<td>R 600</td>
</tr>
</tbody>
</table>

Note: The table is not reproducible.
The fever drop time for the patients is described in Figure 5 and ranges from a minimum of 1 day to a maximum of 12 days.

Figure 5. Legend: a--affections of the respiratory apparatus; b--time of fever drop from beginning of treatment; c--days; e--patients' initials.

We are also describing here a case of residual fever which turned out to be not susceptible to cephaloridine treatment.
Figure 6 shows an example of a bronchial pneumonia episode which was resolved due to the effect of the antibiotic in a very evident fashion. The expectorate, which increased during the first few days, parallel to the transition from the hepatization phase to the resolution phase, decreased quite definitely, and then disappeared within a week. All of the other constants followed the favorable course of the disease.

Figure 6. S. G.: bronchial pneumonia. Legend: a--arterial blood pressure; b--Katz index; c--leucocytes/cubic mm; d--expectorate /sputum/ 24 hours; e--cephaloridine; f--temperature; g--days.

Figure 7 describes the case of an apyretic patient suffering from chronic bronchitis accompanied by an asthmatic ailment with abundant expectoration, treated with cephaloridine. The favorable development in this case was manifested not only by the decrease in the kinetic symptomatology of the respiratory tract, but also by a reduction in the number of asthmatic attacks and above all by the reduction of the expectorate practically down to zero.
The antibiotic dose used in these patients varied between 1-2 g.

Affections of the liver and the bile ducts. The affections of the liver and the bile ducts are represented by patients with septic affections of the liver, patients who are carriers of primary or secondary angiocolechitis or of cyst suppurated by echinococcus (Table 3).

### TABLE 3
SUMMARY TABLE OF CASE HISTORY OF SEPTIC AFFECTIONS OF THE LIVER AND THE BILE DUCTS, TREATED WITH CEPIALORIDINE

<table>
<thead>
<tr>
<th>R.</th>
<th>Patients</th>
<th>(a)</th>
<th>(b)</th>
<th>(c)</th>
<th>(d)</th>
<th>(e)</th>
<th>(f)</th>
<th>(g)</th>
<th>(h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>D. E.</td>
<td>Coleoptica acuta (x)</td>
<td>1</td>
<td>10</td>
<td>19</td>
<td>13</td>
<td>9.000</td>
<td>7.000</td>
<td>Ottimo (i)</td>
</tr>
<tr>
<td>2</td>
<td>C. R.</td>
<td>Coleoptica, sepsis</td>
<td>1</td>
<td>10</td>
<td>19</td>
<td>19</td>
<td>9.000</td>
<td>6.000</td>
<td>Scuro (j)</td>
</tr>
<tr>
<td>3</td>
<td>P. E.</td>
<td>Euparise crumia acuta coelestinifer (c)</td>
<td>1</td>
<td>9</td>
<td>4</td>
<td>126</td>
<td>119</td>
<td>11.000</td>
<td>6.000</td>
</tr>
<tr>
<td>4</td>
<td>L. F.</td>
<td>Euparise crumia (g)</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>20</td>
<td>9.000</td>
<td>6.000</td>
<td>Ottimo</td>
</tr>
<tr>
<td>5</td>
<td>H. L.</td>
<td>Euparise acuta colehepatia (u)</td>
<td>1</td>
<td>15</td>
<td>2</td>
<td>38</td>
<td>13</td>
<td>9.000</td>
<td>5.000</td>
</tr>
<tr>
<td>6</td>
<td>P. G.</td>
<td>Euparise crumia colehepatia acuta (w)</td>
<td>1</td>
<td>15</td>
<td>2</td>
<td>27</td>
<td>57.5</td>
<td>6.000</td>
<td>5.000</td>
</tr>
<tr>
<td>7</td>
<td>M. C.</td>
<td>Cost de echinococcus suppurata (x)</td>
<td>1.5</td>
<td>15</td>
<td>13</td>
<td>20</td>
<td>9.000</td>
<td>7.000</td>
<td>Ottimo</td>
</tr>
<tr>
<td>8</td>
<td>D. M.</td>
<td>Euparise crumia parahepatia</td>
<td>2.5</td>
<td>25</td>
<td>12</td>
<td>37</td>
<td>80</td>
<td>10.000</td>
<td>7.000</td>
</tr>
</tbody>
</table>

Legend: (a) number; (b) patients' initials; (c) form of disease; (d) cephaloridine; (e) VES/sedimentation rate (Kats index); (f) leukocytes; (g) duration of treatment (days); (h) fever drop after number of days; (i) before; (j) after; (k) result; (l) good; (m) excellent; (n) poor; (o) residual fever; (p) not sensitive to other antibiotics; (q) acute cholangitis; (r) cholelithiasis; (s) chronic acutogenic cholecystopathic hepatitis; (t) hepato-cholangitis; (u) acute hepatic cholangitis; (v) chronic hepatitis; (w) acute cholecystitis; (x) suppurated hepatic cyst due to echinococcus; (y) protracted hyperthermic state in cholecystectomy/ [female] patient; (z) comments; (aa) excellent; (bb) good; (cc) poor; (dd) residual fever.

The germ viruses isolated in this part of our group of case histories were enteroccoccus, bacterium Coli, and staphylococcus.

One case of cholelithiasis in a subject who was also a carrier of intestinal tuberculosis, did not respond to the antibiotic.
Figure 7. N. O.: asthmatic bronchitis. Legend: a—arterial blood pressure; b—leucocytes/cubic mm; c—expectorate/24 hours; d—temperature; e—days; f—cephaloridine, 1 g per day.

Figure 8 shows the fever drop time for the patients in this group of case histories.
Figure 8. Legend: a--affections of the liver and the bile ducts; b--time of fever drop from beginning of treatment; c--days; d--patients' initials.

We also think it interesting to point out the case of a 38-year old female patient who revealed a radiological picture and a symptomatology which led to a diagnosis of "multiple liver abscesses in a subject already cholecystectomised" (see the x-ray picture of the liver in Figure 9).

Figure 9. Patient D. M. (female): Direct liver x-ray.

After a period of treatment at the institute with antibiotics, our female patient was discharged although she still had some fever but maintenance treatment was administered with the antibiotic. After about 10 days, she developed a rather bad pain in the right shoulder; the attending physician interpreted this as scapulohumeral pariarthritis; she was treated with a dose of prednisone at the rate of 100 mg per day. After 6 days of treatment,
she had recurrent high fever, intensive pain in the right half of the chest, and her excretion /sputum/ was purulent in nature (Figure 10). We then instituted cephaloridine therapy at the rate of 3 g per day for a period of 10 days and 2 g during the following days; within 4 days the fever dropped, along with the symptomatology. The fever disappeared completely by the 11th day; simultaneously, the leucocytosis returned to normal (Figure 12). The lung picture, in turn, after 20 days revealed a complete clearance, with success in the resynthesis of the costo-phrenic corner /angle/ (Figure 11).

Figure 10. Female patient D.M.: chest x-ray prior to cephaloridine therapy.

Figure 11. Female patient D.M.: x-ray of chest after cephaloridine treatment.
An equally brilliant result was obtained in the group of affections of the bile ducts. Figure 13 describes the behavior of signs imputable to the inflammation process going on in the bile tract; we can observe a definite improvement induced by antibiotic therapy with cephaloridine, as demonstrated by the reduction in the temperature, the VES (sedimentation rate per second or speed of elimination of secretions), the mucoproteins, and the alpha2 globulins.
Figure 13. D.E.: acute cholangitis. Legend: a--seric alpha_2 globulins; b--macoproteins; c--VEE (lata index); d--leucocytes/cubic mm; e--temperature; f--days; f--cephalonride, 1 g/day.

The signs of bile retention also definitely improve, along with the regression in the inflammation process. This was expressed by the reduction in the bilirubinemia, the cholesterolism, and the alkaline phosphatase, as well as the behavior of the color excretion tests (ESF and Cardio-Green), which were performed the nearer the bilirubinemia level had become compatible with the performance of these tests (Figure 14).
On the basis of the data collected, we can say that cephaloridine can penetrate membranes which are rather purely permeable for other antibiotics, with a good coefficient of concentration. This fact became evident, for example, in a case of supported cystic echinococcosis, which responded to treatment in a truly exceptional fashion.

Figures 15 and 16 show the x-rays for bladder expansion due to echinococcosis (voluminous echinococcal cyst), in an antero-posterior and lateral projection; Figure 17 shows the stratigraphic picture after (Fig. beyond) the pneumoperitoneum.
Figure 15. Patient N.C.: suppurated hepatic echinococcosis cyst; chest x-ray in standard projection.

Figure 16. Patient N.C.: suppurated hepatic echinococcosis cyst; chest x-ray in lateral projection.
Figure 17. Patient A.C.: suppurated hepatic echinococosis cyst; stratigraphic image after /beyond/ pneumoperitoneum.

The evolution of the generic constants and the temperature, which had turned out to be very little or not at all sensitive to other antibiotics, are summarized in Figure 18.
Figure 18. M.C.: suppurated hepatic echinococcus cyst. Legend: a--arterial pressure; b--VES (Kats index); c--leucocytes per cubic mm; d--temperature; e--days; f--rifampicin; g--penicillin; h--cephaloridin, 3 g/day; 2 g/day.

Heart diseases. The case histories for the septic heart diseases (Table 4 and Figure 19), although rather scarce here, nevertheless do enable us, on the basis of one case which we followed particularly long and which had been treated with many other antibiotics to no avail, to state that cephaloridin is useful also in these disease forms.
TABLE 4

SUMMARY TABLE OF CASE HISTORIES OF BACTERIAL CARDITIS TREATED WITH CEPIALORIDINE

<table>
<thead>
<tr>
<th>No.</th>
<th>Patients</th>
<th>Forma morbis</th>
<th>Z. Z.</th>
<th>Dose</th>
<th>Pneumocystis</th>
<th>Pneumocystis</th>
<th>K. K.</th>
<th>M. M.</th>
<th>V. V.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>D. A</td>
<td>Endocardia reumatica</td>
<td>(c)</td>
<td>18 h.</td>
<td>25</td>
<td>35</td>
<td>22</td>
<td>7.400</td>
<td>6.800</td>
</tr>
<tr>
<td>2</td>
<td>R. R</td>
<td>Endocardia bacterica</td>
<td>(q)</td>
<td>21 h.</td>
<td>21</td>
<td>30</td>
<td>20</td>
<td>10.000</td>
<td>5.000</td>
</tr>
<tr>
<td>3</td>
<td>M. E</td>
<td>Pericardia acuta, bronchitis cronica</td>
<td>(r)</td>
<td>17 h.</td>
<td>17</td>
<td>15</td>
<td>15</td>
<td>7.000</td>
<td>6.800</td>
</tr>
<tr>
<td>4</td>
<td>P. P</td>
<td>Pericardia acuta</td>
<td>(m)</td>
<td>17 h.</td>
<td>17</td>
<td>15</td>
<td>15</td>
<td>7.000</td>
<td>6.800</td>
</tr>
</tbody>
</table>

Legend: a--number; b--patients' initials; c--form of disease; d--cephaloridine; e--VES [sedimentation rate] (Kats index); f--leucocytes; g--duration of treatment (days); h--% var drop after number of days; i--before; j--after; k--result; l--comments; m--excellent; n--good; o--discreet; p--residual fever; q--not sensitive to other antibiotics; r--rheumatic endocarditis; s--bacterial endocarditis due to S. viridans; t--acute pericarditis, chronic bronchitis; u--acute pericarditis.

Figure 19. Legends

Legend: a--bacterial pericardites and endocardites; b--time of fever disappearance from beginning of treatment; c--days; d--patients' initials.

Figure 20 represents a graphic recording of the temperature of a young male patient suffering from streptococcic endocarditis; this case had not responded to a long series of antibiotics. As we can see quite clearly from the graph, it was cephaloridine which ended the state of sickness in 6 days, after the disease had earlier appeared irreducible.
Miscellaneous affections. Data on the other cases treated here can be found in Table 5 and Figure 21. We can say that in most of these cases we were able to end the fever within 3-4 days. Only 1 case of chronic tonsillitis and a hyperthermic state in a cholecystectomized male patient did not respond to the treatment.

One portion of our cases did not respond to antibiotic treatment initiated upon admission in an absolute fashion, with respect to the fever curve profile. However, these cases, upon further investigation, turned out to consist of affections not susceptible to antibiotic treatment.

Study of liver cell functional tests and other blood-chemistry constants. Our investigation was aimed primarily at the synthetic and detoxifying activities of the liver.
### Table 5

**SUMMARY TABLE OF CASE HISTORIES INCLUDING MISCELLANEOUS AFFECTIONS TREATED WITH CEPHALORIDINE**

<table>
<thead>
<tr>
<th>No.</th>
<th>Patient</th>
<th>Disease</th>
<th>Full name</th>
<th>(a) Name</th>
<th>(b) Tonsillitis</th>
<th>(c) Tonsillitis or streptococcal sore throat</th>
<th>(d) Duration of treatment (days)</th>
<th>(e) Leucocytes</th>
<th>Remarks</th>
<th>(f) Result</th>
<th>(k) Treatment</th>
<th>(l) Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>V. M.</td>
<td>Tonsillitis</td>
<td>V. M.</td>
<td>Tonsillitis</td>
<td>5 5</td>
<td>4 3</td>
<td>300</td>
<td>200</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. A.</td>
<td>Tonsillitis</td>
<td>S. A.</td>
<td>Tonsillitis</td>
<td>4 4</td>
<td>8 8</td>
<td>1200</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. E.</td>
<td>Tonsillitis</td>
<td>E. E.</td>
<td>Tonsillitis</td>
<td>2 2</td>
<td>2 2</td>
<td>3000</td>
<td>1000</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. M.</td>
<td>Tonsillitis</td>
<td>M. M.</td>
<td>Tonsillitis</td>
<td>3 3</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. M.</td>
<td>Tonsillitis</td>
<td>S. M.</td>
<td>Tonsillitis</td>
<td>4 4</td>
<td>6 6</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Z. O.</td>
<td>Tonsillitis</td>
<td>Z. O.</td>
<td>Tonsillitis</td>
<td>5 5</td>
<td>4 4</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>H. C.</td>
<td>Tonsillitis</td>
<td>H. C.</td>
<td>Tonsillitis</td>
<td>6 6</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I. D.</td>
<td>Tonsillitis</td>
<td>I. D.</td>
<td>Tonsillitis</td>
<td>7 7</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. R.</td>
<td>Tonsillitis</td>
<td>C. R.</td>
<td>Tonsillitis</td>
<td>8 8</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. L.</td>
<td>Tonsillitis</td>
<td>L. L.</td>
<td>Tonsillitis</td>
<td>9 9</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. M.</td>
<td>Tonsillitis</td>
<td>S. M.</td>
<td>Tonsillitis</td>
<td>10 10</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. D.</td>
<td>Tonsillitis</td>
<td>J. D.</td>
<td>Tonsillitis</td>
<td>11 11</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. R.</td>
<td>Tonsillitis</td>
<td>C. R.</td>
<td>Tonsillitis</td>
<td>12 12</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. L.</td>
<td>Tonsillitis</td>
<td>L. L.</td>
<td>Tonsillitis</td>
<td>13 13</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. M.</td>
<td>Tonsillitis</td>
<td>S. M.</td>
<td>Tonsillitis</td>
<td>14 14</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. D.</td>
<td>Tonsillitis</td>
<td>J. D.</td>
<td>Tonsillitis</td>
<td>15 15</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. R.</td>
<td>Tonsillitis</td>
<td>C. R.</td>
<td>Tonsillitis</td>
<td>16 16</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. L.</td>
<td>Tonsillitis</td>
<td>L. L.</td>
<td>Tonsillitis</td>
<td>17 17</td>
<td>5 5</td>
<td>3000</td>
<td>500</td>
<td>Good</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- a—number
- b—patients' initials
- c—form of disease
- d—cephaloridine
- e—ves/sedimentation rate/ (Katz index)
- f—leucocytes
- p—duration of treatment (days)
- i—before
- j—after
- k—result
- l—comments
- m—excellent
- n—good
- o—discreet
- p—residual fever
- q—poor
- r—associated prednisone therapy
- s—not sensitive to any antibiotic
- t—unchanged fever picture
- u—nothing
- v—chronic tonsillitis
- w—chronic tonsillitis, rheumatic disease
- x—chronic pharyngitis
- y—associated prednisone therapy
- z—hyperthermia in cholecystectomy performed patient
- aa—erythematous to test for amphotericin
- bb—erythematous to test for amphotericin
- cc—Dysthermia in neurolyticoma performed patient
- dd—hyperthermia in cholecystectomy performed patient
- ee—hyperthermia in cholecystectomy performed patient
- ff—malignant lymphogranuloma
- gg—reticulosarcoma

---

"SUMMARY TABLE OF CASE HISTORIES INCLUDING MISCELLANEOUS AFFECTIONS TREATED WITH CEPHALORIDINE"
Figure 21. Legend: a—miscellaneous affections; b—time of fever disappearance from start of treatment; c—days; d—patients' initials.

The synthetic activities of the liver cell (albuminemia, cholinesterase, prothrombinic activities, V factor and VII factor) in all groups of patients studied revealed that they do not respond negatively to the administration of the antibiotic, even when the antibiotic is administered at high doses (Figure 22).
Figure 22. Behavior of tests indicating synthetic capacities of liver cell, before and after treatment with cephaloridine. Legend: a--case histories; b--kidney; c--lung; d--liver; e--heart; f--miscellaneous; g--cholinesterase; h--albumin; i--prothrombinic activity; j--V factor; k--VII factor; P--before; D--after.

The excretion tests made on the liver (bilirubinemia, elimination of Cardio-Green, and of bromosulfonphthalein), azotemia, glycemia, and blood cholesterol revealed similar behavior (Figures 23 and 24).

Figure 23. Behavior of excretory functions of liver, before and after administration of cephaloridine. Legend: a--case histories; b--kidney; c--lung; d--liver; e--heart; f--miscellaneous; g--percentages; h--bilirubinemia; i--excretion of Cardio-Green per 100 ml; j--retention of BSF after 45'; P--before; D--after.

Figure 24 (Legend on following page)
Figure 24. Behavior of asotemia, glyceria, and cholesterolesia, before and after treatment with cephaloridine. Legend: a--case histories; b--kidney; c--lung; d--liver; e--heart; f--miscellaneous; g--asotemia; h--glyceria; i--cholesterolisma; P--before; D--after.

Cephaloridine does not induce modifications in the membrane of the liver cell. As a matter of fact, we were unable to demonstrate in any of the patients that there was a serious variation in the output enzymes (Figure 25).

![Figure 25](image-url)

Figure 25. Behavior of asotemia, glyceria, and cholesterolesia, before and after treatment with cephaloridine. Legend: a--case histories; b--kidney; c--lung; d--liver; e--heart; f--miscellaneous; P--before; D--after.

In Figure 26 we have the behavior of the speed of elimination of Cardio-Dreem and the percentage of retention of BSF before and after acute injection of 2 g of cephaloridine. This tells us that neither of the two tests expressing the excretory and detoxicating capacity of the liver is modified by the injection of antibiotics.
Figure 26. Influence of cephaloridine on rate of excretion of Cardio-Green and percentage of retention of BSF. Legend: a—rate of excretion per minute; b—BSF retention after 15'; c—before administration of cephaloridine; d—4 hours after administration of cephaloridine (2 g); e—hours.

Conclusions

On the basis of the data reported here we can say that cephaloridine can be considered, without further ado, to be an antibiotic which acts promptly and which displays a rather high activity level; it also has an extremely low toxicity (29, 31, 34, 35, 37, 38). In all of our case histories we only had two cases which revealed signs of toxicity that could be related to the antibiotic; these signs were represented by glossitis, stomatitis, and esophagitis as well as some diarrheic discharge, but these manifestations disappeared completely the minute the therapy was discontinued.

This antibiotic did not interfere with the synthetic capacities of the liver cell in any of our cases. As regard the excretory capacity of the liver, we do know (4) that some antibiotics tend to compete with the excretion of bilirubin and also with respect to the excretion of colors (Cardio-Green, BSF); but the pharmaceutical which we used definitely did not produce any action along these lines.

Its truly remarkable activity with respect to kidney affections is explained by the excretion through that outlet. Cephaloridine is characterised by a high coefficient of distribution in the various organs and systems;
this justifies and explains the prompt effect also in affections located in the lungs, the liver, the heart, etc. (26).

Finally, we think we ought to emphasize here the rather high tendency of cephaloridine to diffuse across the inflammatory barriers, as was demonstrated by the excellent result obtained from its use in the case of a suppurated echinococcus cyst. This is probably another reason for the brilliant result obtained during cases of bacterial endocarditis which had earlier been treated to no avail with other antibiotics which are less diffusible.

W. Moguardi - G. Iseo
 Ist. d. Patologia Speciale Medica dell'Univ. - Cagliari.

Bibliography


